Compare GSK plc (GSK) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs ArcelorMittal SA — how do they compare? GSK plc trades at $46.82 (market cap $91.88B), while ArcelorMittal SA trades at $64.17 (market cap $45.70B). The key difference: GSK plc is far larger — about 2× ArcelorMittal SA's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and ArcelorMittal SA for 36 Days on average.
| GSK | MT | |
|---|---|---|
Market Cap | $91.88B | $45.70B |
Volume | 7,730,529 | 1,964,621 |
Sector | Health | Basic Materials |
52-Week High | $61.18 | $78.74 |
52-Week Low | $43.24 | $36.91 |
Typical Hold Time | 93 Days | 36 Days |
Enterprise Value | $111.88B | $55.27B |
Dividend Yield | 3.9% | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
ArcelorMittal (MT) trades at $62.32, down 4.4% on the day, amid a bearish technical setup and recent operational disruptions in Ukraine. The stock shows mixed fundamentals with a low P/S of 0.75 and P/B of 0.84, but profitability metrics like net margin (2.88%) and ROE (3.32%) remain modest. Recent Q2 2026 earnings missed estimates, though Q1 and Q4 2025 beat expectations. Analyst consensus is bullish with a $74.33 price target, but technical indicators signal caution.
The outlook is clouded by near-term headwinds including the Ukraine plant impairment and volatile steel demand, yet long-term value is supported by low valuation multiples and strategic regionalization efforts. Risks include geopolitical exposure and cyclical industry pressures, but institutional sentiment remains positive with 52% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
